Full-Time

Associate Director

Clinical Quality

Posted on 6/26/2025

Tr1X

Tr1X

11-50 employees

Develops cellular immunotherapies for autoimmune diseases

Compensation Overview

$175k - $200k/yr

+ Discretionary annual target bonus + Stock options + 401(k) contributions

San Diego, CA, USA

In Person

Category
Legal & Compliance (1)
Requirements
  • Bachelor’s degree in a scientific discipline or an equivalent combination of education, training and/or experience from which comparable knowledge, skills and abilities have been attained.
  • Minimum 8 years of related experience with a minimum 5 years of experience in clinical quality management in the pharmaceutical or biotech industry.
  • Experience and knowledge in the establishment and management of quality systems, vendor and investigator site audits, and CRO oversight.
  • Working knowledge and adherence to FDA, ISO and ICH regulatory guidance and regulations, clinical quality operations, and CTD/eCTD standards.
  • Exceptional interpersonal skills with the ability to effectively develop supportive and collaborative relationships.
  • Superior organizational, communication, and problem-solving skills.
  • Highly proficient in MS Office 365 (with an emphasis on MS Word).
  • Legally authorized to work for any employer in the U.S.
  • Periodic travel is required to CROs and vendor sites.
  • Position is based in San Diego, CA.
Responsibilities
  • Oversee all aspects of Clinical Quality for internal and external processes, including CROs, vendors, and investigator sites.
  • Review internal and external documentation to ensure quality, regulatory compliance and audit-readiness.
  • Document internal regulatory processes and evaluate quality events, incidents, queries, and complaints.
  • Utilize guidance regulatory documents, international standards, and industry standards and interpret and apply to clinical trials and activities.
  • Conduct audits of clinical documentation, investigator sites, vendors, systems.
  • Lead root cause analyses and implement corrective and preventive action plans.
  • Collaborate with internal and external stakeholders to align quality strategies with organizational goals.
  • Assume a lead role in representing clinical quality at internal meetings and in preparing and drafting clinical quality policies, procedures, regulatory submissions and GCP training.
  • Communicate any critical compliance risks to senior management and recommend possible solutions.
  • Assist in the development of documentation and implementation of systems and SOPs.
  • Support all Quality team needs as identified by management.
  • Keep abreast of and make recommendations to management on new or revised regulations, guidelines, points to consider, compliance guides, inspection reports, journals, meetings, etc.
  • Perform other responsibilities as required by business needs.
Desired Qualifications
  • Experience with cell therapy products and prior participation in regulatory inspections desirable.

Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.

Company Size

11-50

Company Stage

Early VC

Total Funding

$125M

Headquarters

San Diego, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared INDs for TRX103 in GvHD and TRX319 in MS, trials advancing with positive safety data.
  • Secured $75M Series A from Column Group and $50M financing plus $8M CIRM grant.
  • San Diego biotech hub provides talent access near UCSD and 400+ local companies.

What critics are saying

  • Manufacturing scale-up fails, halting TRX103 and TRX319 GMP production within 12-24 months.
  • TRX319 Phase 1 triggers cytokine release safety signal, terminating MS program in 6-18 months.
  • Regeneron and AstraZeneca displace Tr1X with faster Treg efficacy readouts in 18-36 months.

What makes Tr1X unique

  • Tr1X engineers allogeneic Tr1 Treg cells mimicking natural Tr1 cells for superior inflammation homing.
  • Proprietary platform enables scalable off-the-shelf CAR-Treg therapies like TRX319 for progressive MS.
  • Founded on Dr. Maria Grazia Roncarolo's Tr1 cell discovery, first in clinical trials.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

401(k) Company Match

Flexible Work Hours

Stock Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

4%
San Diego Business Journal
Oct 27th, 2025
Tr1X Bio Secures $50M Funding

Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.

GlobeNewswire
Oct 14th, 2025
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...

Clinical Trial Vanguard
Apr 7th, 2025
TR1X Awarded $8M Grant for TRX103 GvHD Trial

TR1X awarded $8M grant for TRX103 GvHD trial.

Benzinga
Apr 4th, 2025
Tr1X Awarded $8 Million Cirm Grant To Support Trx103 Phase 1/2A Clinical Trial For Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025

TMCnet
Apr 4th, 2025
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.

INACTIVE